Chairperson of the topmost Pharmaceutical company, Pharmexcil, which earns 40 - 50 per cent of its total revenues from the American market also said, "Generic drugs are not impacted".
The Indian pharmaceutical industry requires price increases, site and intellectual property (IP) transfers to deal with the prevailing uncertainty in the sector amid US tariffs, according to a report by Systematix Research
Indian pharmaceutical manufacturers are preparing a two-pronged strategy to offset the impact of the soon-to-be-effective 25 per cent US tariff on Indian goods, which includes drug exports, with industry experts anticipating that the move could significantly raise medicine costs in the Ameri
The executive order signed by President Donald Trump on Thursday has imposed flat 25 per cent tariff on all goods from India, with no product-level exemptions, according to a report by the Global Trade Research Initiative (GTRI).
The Indian pharmaceutical industry has hit back strongly at the recent tariff announcement by U.S. President Donald Trump, calling it a move that could hurt the American healthcare system more than India's economy.
Habil Khorakiwala, Chairman of pharma company Wockhardt on Friday indicated that any imposition of tariffs on pharma products by the US administration would be counterproductive for the Americans.
Siddharth Mittal, CEO and Managing Director of Biocon Limited, said on Friday asked who would pay the price to shift their shops in the US where pharma manufacturing costs are higher than in India and China.